Clinical Trial: Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Pancreatic Cancer
Study Type: INTERVENTIONAL
Official Title: Role of Cholecystokinin Receptor Blockade on the Tumor Microenvironment in Pancreatic Cancer
Brief Summary:
This is a Phase 2 study with an open labelled lead-in study to approximately treat 30 patients [6 subjects for Lead-in and 24 for Phase 2] enrolled with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with GEM-NAB-P (GEM 1000mg/m2 IV and NAB-P 125 mg/m2 given days 1, 8, and 15 every 28 days, and proglumide will be tested at the daily dose of 1200 mg orally given as 400 mg po TID.The lead-in study will determine the safety and tolerability of the 1200 mg…
Read more